Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04580277 · ClinicalTrials.gov registry record · Phase 2

Tofacitinib For Treatment Of Chronic Pouchitis

A Phase 2 study, sponsored by Cedars-Sinai Medical Center.

Terminated
Registry status
Phase 2
Development phase
6
Enrollment target

NCT04580277 is a Phase 2 study that was terminated before completion, run by Cedars-Sinai Medical Center. The registered enrollment target is 6 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04580277, a Phase 2 study, was terminated before completion, sponsored by Cedars-Sinai Medical Center.

TERMINATED
Registry status
Phase 2
Development phase
6 participants
Enrollment target

Study Summary

A phase 2 pilot study to evaluate the effectiveness of tofacitinib in subjects with chronic pouchitis

Interventions

  • DRUG Tofacitinib 10 mg

Trial Details

FieldValue
Enrollment Target 6 participants
Start Date 2021-01-25
Est. Completion 2023-05-15
Phase Phase 2

Sponsor

Cedars-Sinai Medical Center

339 total trials

What the Registry Record Tells You About NCT04580277

The ClinicalTrials.gov registry entry for NCT04580277 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 6 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Cedars-Sinai Medical Center, which has 339 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 1 intervention - of which Tofacitinib 10 mg is the first listed.

NCT04580277 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT04580277 about?

NCT04580277 is a clinical study titled "Tofacitinib For Treatment Of Chronic Pouchitis". A phase 2 pilot study to evaluate the effectiveness of tofacitinib in subjects with chronic pouchitis

What is the current status of trial NCT04580277?

This trial is currently terminated. It is a Phase 2 study. The enrollment target is 6 participants. The study started on 2021-01-25. Estimated completion is 2023-05-15.

What interventions are being tested in trial NCT04580277?

The interventions under investigation include: Tofacitinib 10 mg (DRUG).

Who is sponsoring clinical trial NCT04580277?

This trial is sponsored by Cedars-Sinai Medical Center, which has 339 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.